1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Metabolic Disease Therapeutics Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
1.2.2 Glycogen Metabolism Disease Drug
1.2.3 Lipid Metabolism Disease Drug
1.2.4 Amino Acid Metabolism Drug
1.2.5 Other
1.3 Market by Application
1.3.1 Global Metabolic Disease Therapeutics Market Share by Application: 2017 VS 2021 VS 2028
1.3.2 Hospital Pharmacy
1.3.3 Retail Pharmacy
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Metabolic Disease Therapeutics Market Perspective (2017-2028)
2.2 Metabolic Disease Therapeutics Growth Trends by Region
2.2.1 Metabolic Disease Therapeutics Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Metabolic Disease Therapeutics Historic Market Size by Region (2017-2022)
2.2.3 Metabolic Disease Therapeutics Forecasted Market Size by Region (2023-2028)
2.3 Metabolic Disease Therapeutics Market Dynamics
2.3.1 Metabolic Disease Therapeutics Industry Trends
2.3.2 Metabolic Disease Therapeutics Market Drivers
2.3.3 Metabolic Disease Therapeutics Market Challenges
2.3.4 Metabolic Disease Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Metabolic Disease Therapeutics Players by Revenue
3.1.1 Global Top Metabolic Disease Therapeutics Players by Revenue (2017-2022)
3.1.2 Global Metabolic Disease Therapeutics Revenue Market Share by Players (2017-2022)
3.2 Global Metabolic Disease Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Metabolic Disease Therapeutics Revenue
3.4 Global Metabolic Disease Therapeutics Market Concentration Ratio
3.4.1 Global Metabolic Disease Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Metabolic Disease Therapeutics Revenue in 2021
3.5 Metabolic Disease Therapeutics Key Players Head office and Area Served
3.6 Key Players Metabolic Disease Therapeutics Product Solution and Service
3.7 Date of Enter into Metabolic Disease Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Metabolic Disease Therapeutics Breakdown Data by Type
4.1 Global Metabolic Disease Therapeutics Historic Market Size by Type (2017-2022)
4.2 Global Metabolic Disease Therapeutics Forecasted Market Size by Type (2023-2028)
5 Metabolic Disease Therapeutics Breakdown Data by Application
5.1 Global Metabolic Disease Therapeutics Historic Market Size by Application (2017-2022)
5.2 Global Metabolic Disease Therapeutics Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Metabolic Disease Therapeutics Market Size (2017-2028)
6.2 North America Metabolic Disease Therapeutics Market Size by Country (2017-2022)
6.3 North America Metabolic Disease Therapeutics Market Size by Country (2023-2028)
6.4 United States
6.5 Canada
7 Europe
7.1 Europe Metabolic Disease Therapeutics Market Size (2017-2028)
7.2 Europe Metabolic Disease Therapeutics Market Size by Country (2017-2022)
7.3 Europe Metabolic Disease Therapeutics Market Size by Country (2023-2028)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Metabolic Disease Therapeutics Market Size (2017-2028)
8.2 Asia-Pacific Metabolic Disease Therapeutics Market Size by Country (2017-2022)
8.3 Asia-Pacific Metabolic Disease Therapeutics Market Size by Country (2023-2028)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
9 Latin America
9.1 Latin America Metabolic Disease Therapeutics Market Size (2017-2028)
9.2 Latin America Metabolic Disease Therapeutics Market Size by Country (2017-2022)
9.3 Latin America Metabolic Disease Therapeutics Market Size by Country (2023-2028)
9.4 Mexico
9.5 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Metabolic Disease Therapeutics Market Size (2017-2028)
10.2 Middle East & Africa Metabolic Disease Therapeutics Market Size by Country (2017-2022)
10.3 Middle East & Africa Metabolic Disease Therapeutics Market Size by Country (2023-2028)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
11 Key Players Profiles
11.1 Merck
11.1.1 Merck Company Detail
11.1.2 Merck Business Overview
11.1.3 Merck Metabolic Disease Therapeutics Introduction
11.1.4 Merck Revenue in Metabolic Disease Therapeutics Business (2017-2022)
11.1.5 Merck Recent Development
11.2 Novartis
11.2.1 Novartis Company Detail
11.2.2 Novartis Business Overview
11.2.3 Novartis Metabolic Disease Therapeutics Introduction
11.2.4 Novartis Revenue in Metabolic Disease Therapeutics Business (2017-2022)
11.2.5 Novartis Recent Development
11.3 Takeda Pharmaceutical
11.3.1 Takeda Pharmaceutical Company Detail
11.3.2 Takeda Pharmaceutical Business Overview
11.3.3 Takeda Pharmaceutical Metabolic Disease Therapeutics Introduction
11.3.4 Takeda Pharmaceutical Revenue in Metabolic Disease Therapeutics Business (2017-2022)
11.3.5 Takeda Pharmaceutical Recent Development
11.4 Astra Zeneca
11.4.1 Astra Zeneca Company Detail
11.4.2 Astra Zeneca Business Overview
11.4.3 Astra Zeneca Metabolic Disease Therapeutics Introduction
11.4.4 Astra Zeneca Revenue in Metabolic Disease Therapeutics Business (2017-2022)
11.4.5 Astra Zeneca Recent Development
11.5 Beohrigher Ingelheim
11.5.1 Beohrigher Ingelheim Company Detail
11.5.2 Beohrigher Ingelheim Business Overview
11.5.3 Beohrigher Ingelheim Metabolic Disease Therapeutics Introduction
11.5.4 Beohrigher Ingelheim Revenue in Metabolic Disease Therapeutics Business (2017-2022)
11.5.5 Beohrigher Ingelheim Recent Development
11.6 KOWA
11.6.1 KOWA Company Detail
11.6.2 KOWA Business Overview
11.6.3 KOWA Metabolic Disease Therapeutics Introduction
11.6.4 KOWA Revenue in Metabolic Disease Therapeutics Business (2017-2022)
11.6.5 KOWA Recent Development
11.7 Kythera
11.7.1 Kythera Company Detail
11.7.2 Kythera Business Overview
11.7.3 Kythera Metabolic Disease Therapeutics Introduction
11.7.4 Kythera Revenue in Metabolic Disease Therapeutics Business (2017-2022)
11.7.5 Kythera Recent Development
11.8 Fuji yakuhin
11.8.1 Fuji yakuhin Company Detail
11.8.2 Fuji yakuhin Business Overview
11.8.3 Fuji yakuhin Metabolic Disease Therapeutics Introduction
11.8.4 Fuji yakuhin Revenue in Metabolic Disease Therapeutics Business (2017-2022)
11.8.5 Fuji yakuhin Recent Development
11.9 LG Life Science
11.9.1 LG Life Science Company Detail
11.9.2 LG Life Science Business Overview
11.9.3 LG Life Science Metabolic Disease Therapeutics Introduction
11.9.4 LG Life Science Revenue in Metabolic Disease Therapeutics Business (2017-2022)
11.9.5 LG Life Science Recent Development
11.10 Metsubishi Tanabe Pharma
11.10.1 Metsubishi Tanabe Pharma Company Detail
11.10.2 Metsubishi Tanabe Pharma Business Overview
11.10.3 Metsubishi Tanabe Pharma Metabolic Disease Therapeutics Introduction
11.10.4 Metsubishi Tanabe Pharma Revenue in Metabolic Disease Therapeutics Business (2017-2022)
11.10.5 Metsubishi Tanabe Pharma Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
